U.S. label record^↗Metabolic^↗

Liraglutide^↗

Related names in cited records: Saxenda^↗

A GLP-1 receptor agonist. This profile cites a U.S. label record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 29, 2026

We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change. ²

This version supersedes public version 2.

Evidence summary

What the cited records say

The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

U.S. National Library of Medicine^↗

Dated source history

Updates connected to this profile

April 30, 2026
Regulatory
FDA proposes excluding three GLP-1 ingredients from the 503B bulks list^↗
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.^↗
January 13, 2026
Safety
FDA requests removal of a warning from certain GLP-1 drug labels^↗
FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.^↗

What the cited records say

Related records

Organizations named in cited records

Updates connected to this profile

FDA proposes excluding three GLP-1 ingredients from the 503B bulks list↗

FDA requests removal of a warning from certain GLP-1 drug labels↗

FDA proposes excluding three GLP-1 ingredients from the 503B bulks list^↗

FDA requests removal of a warning from certain GLP-1 drug labels^↗